Back
August 3 deadline highlighted in GeneDx securities class action

August 3 deadline highlighted in GeneDx securities class action

Faruqi & Faruqi says investors who bought GeneDx shares between April 16, 2025 and May 4, 2026 may seek lead plaintiff status in a case tied to reimbursement rates, margins and Fabric Genomics.

Fact Check
Two independent law-firm press releases on GlobeNewswire (Faruqi & Faruqi and Bernstein Liebhard), both dated July 29, 2026, confirm every element of the claim: the January 30, 2026 IPO, the August 4, 2026 lead plaintiff deadline, eligibility for investors in/traceable to the IPO, and allegations centered on undisclosed credit-quality and underwriting weaknesses. The Faruqi release provides specific factual support for the 'credit-quality and underwriting' framing (credit evaluation deficiencies, Stage 2-to-Stage 3 reclassification, expected credit loss charge). These are primary announcements from the firms making the statements, so the fact that firms are making these announcements is directly verified.
    Reference: 12
Summary

Faruqi & Faruqi, LLP said investors who purchased or acquired GeneDx Holdings Corp. securities between April 16, 2025 and May 4, 2026 have until August 3, 2026 to seek appointment as lead plaintiff in a federal securities class action. The complaint alleges GeneDx and its executives made false or misleading statements, or omitted material information, about the importance of Fabric Genomics, the durability of average reimbursement rates, and the effect those factors would have on margins and gross margins. The release says GeneDx disclosed after market close on May 4, 2026 that first-quarter results missed expectations in both its exome and genome lines and that it cut 2026 revenue guidance to $475 million-$490 million from $540 million-$555 million. During the related earnings call, the company also disclosed an average reimbursement rate of $3,300, about $200 below expectations, and a $31.3 million goodwill impairment charge tied to the Fabric Genomics acquisition, which it had purchased for $36.5 million about a year earlier. On that news, GeneDx shares fell more than 49%, or $33.42 per share, from the prior close. The firm said eligible investors do not need to seek lead plaintiff status to remain in the proposed class and share in any potential recovery.

Terms & Concepts
  • lead plaintiff: The court-appointed investor who directs a securities class action on behalf of the proposed class.
  • goodwill impairment charge: An accounting write-down taken when an acquired business is judged to be worth less than the value previously recorded on the balance sheet.
  • average reimbursement rate: The average amount a company receives from payers for its services or tests, a key metric for revenue and margins in healthcare businesses.